Saturday 17 October 2026
Export VECT’s income statement to Excel — free account
VectivBio Holding AG
VECT Healthcare Biotechnology
VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
Follow VECT
| Dec '22 | Jun '22 | Dec '21 | Jun '21 | Older periods | |
|---|---|---|---|---|---|
| (147.18%) | 0.00% | 0.00% | — |
+2 more TTM periods Free account |
|
| (111.86%) | 0.00% | 0.00% | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(89.51%) | (133.16%) | (157.55%) | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(176.61) | — | — | — | |
Capital Expenditures |
(0.24) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(39.68%) | 0.00% | 0.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.98 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
2.05 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.26) | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates